MK-1308A-008
Evaluation of Co-formulated Pembrolizumab/Quavonlimab Versus Other Treatments in Participants With Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Cancer
Active, Not Recruiting
Trial purpose
The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.
NATIONAL TRIAL REFERENCE NUMBER
NCT04895722
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Colorectal Cancer
Age Range
18+
Sex
Male/Female
Study Details
Current trial Phase
Phase 2
Tests the medicine or vaccine in approximately 100 to 500 participants. In the case of medicines, participants usually have the disease or condition the investigational medicine is designed to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Trial start date 06-25-2021
- Estimated primary completion date 05-21-2025
- Estimated trial completion date 08-06-2026
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
Sorry, there are no locations found.